These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38738340)

  • 21. Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis.
    Azuri J; Hammerman A; Aboalhasan E; Sluckis B; Arbel R
    Diabetes Obes Metab; 2023 Apr; 25(4):961-964. PubMed ID: 36507900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada.
    Pollock RF; Norrbacka K; Cameron C; Mancillas-Adame L; Jeddi M
    J Comp Eff Res; 2019 Mar; 8(4):229-240. PubMed ID: 30644328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
    Hunt B; Hansen BB; Ericsson Å; Kallenbach K; Ali SN; Dang-Tan T; Malkin SJP; Valentine WJ
    Adv Ther; 2019 Dec; 36(12):3483-3493. PubMed ID: 31650514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
    Viljoen A; Hoxer CS; Johansen P; Malkin S; Hunt B; Bain SC
    Diabetes Obes Metab; 2019 Mar; 21(3):611-621. PubMed ID: 30362224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
    Franch-Nadal J; Malkin SJP; Hunt B; Martín V; Gallego Estébanez M; Vidal J
    Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m
    Dilla T; Alexiou D; Chatzitheofilou I; Ayyub R; Lowin J; Norrbacka K
    J Med Econ; 2017 May; 20(5):443-452. PubMed ID: 28008768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison.
    Vadher K; Patel H; Mody R; Levine JA; Hoog M; Cheng AY; Pantalone KM; Sapin H
    Diabetes Obes Metab; 2022 Sep; 24(9):1861-1868. PubMed ID: 35589616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan.
    Ishii H; Madin-Warburton M; Strizek A; Thornton-Jones L; Suzuki S
    J Med Econ; 2018 May; 21(5):488-496. PubMed ID: 29357718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China.
    Hu S; Su X; Deng X; Wang Y
    Front Pharmacol; 2021; 12():701446. PubMed ID: 34177604
    [No Abstract]   [Full Text] [Related]  

  • 30. Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.
    Tobaiqy M; Elkout H
    Int J Clin Pharm; 2024 Apr; 46(2):488-495. PubMed ID: 38265519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States.
    Cui J; Klepser DG; McAdam-Marx C
    J Manag Care Spec Pharm; 2021 Jul; 27(7):840-845. PubMed ID: 34185562
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden.
    Ericsson Å; Fridhammar A
    J Med Econ; 2019 Oct; 22(10):997-1005. PubMed ID: 31044636
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
    Martín V; Vidal J; Malkin SJP; Hallén N; Hunt B
    Adv Ther; 2020 Oct; 37(10):4427-4445. PubMed ID: 32862365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates.
    Reitzel SB; Bøgelund M; Basse A; Barszczewska O; Ren H
    Curr Med Res Opin; 2023 Aug; 39(8):1055-1060. PubMed ID: 37415503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-utility analysis and drug pricing of once-weekly insulin icodec versus once-daily insulin degludec for type 2 diabetes patients treated with basal insulin in China.
    Hu S; Wang S; Gu S; Qi C; Shi C; Fan G
    Diabetes Obes Metab; 2024 Dec; 26(12):5995-6006. PubMed ID: 39344844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
    Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT
    Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tirzepatide: A Review in Type 2 Diabetes.
    France NL; Syed YY
    Drugs; 2024 Feb; 84(2):227-238. PubMed ID: 38388874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics.
    Risebrough NA; Baker TM; Zhang L; Ali SN; Radin M; Dang-Tan T
    Clin Ther; 2021 Nov; 43(11):1812-1826.e7. PubMed ID: 34728099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review.
    Ruan Z; Yang L; Shi H; Yue X; Wang Y; Liang M; Hu H
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):221-233. PubMed ID: 33317348
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
    Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
    Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.